Table 127Mean differences (95% CrI) from conventional (white area) and network meta-analysis (grey area) for FEV1 % predicted with short-term treatment

PlaceboMacrolide antibioticsInhaled corticosteroids
Placebo 2.16 (0.52, 3.79) -2.00 (-7.65, 3.67)
Macrolide antibiotics2.16 (0.52, 3.79)
Inhaled corticosteroids-2.00 (-7.65, 3.67)-4.16 (-10.04, 1.75)

Results in the top right diagonal of the table are the mean differences and 95% CrI from the conventional metaanalyses of direct evidence between the column-defined treatments compared to the row-defined treatment. Mean differences greater than 0 favour the column-defined treatment.

Results in the bottom left are the mean differences and 95% CrI from the NMA model of direct and indirect evidence between the row-defined treatments compared to the column-defined treatments. Mean differences greater than 0 favour the row-defined treatment.

Numbers in bold denote results for which the 95% CrI does not include the null effect of 0

From: 9, Pulmonary monitoring, assessment and management

Cover of Cystic Fibrosis
Cystic Fibrosis: Diagnosis and management.
NICE Guideline, No. 78.
National Guideline Alliance (UK).
Copyright © NICE 2017.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.